Tech Company Financing Transactions

DecImmune Therapeutics Funding Round

On 1/17/2013, DecImmune Therapeutics announced $2.3 million in Series A funding from Astellas Venture Capital, Broadview Ventures and HealthCare Ventures.

Transaction Overview

Company Name
DecImmune Therapeutics
Announced On
1/17/2013
Transaction Type
Venture Equity
Amount
$2,250,000
Round
Series A
Investors

Astellas Venture Capital (Shinya Yano)

Broadview Ventures (Christopher Colecchi)

HealthCare Ventures (Christopher Mirabelli)

Proceeds Purpose
The funding announced today will support preclinical development of DecImmune's therapeutic program targeting heart failure as an adjunct to current standards of care. Heart attack remains the leading cause of death in the United States, responsible for 1.2 million deaths per year.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
47 Thorndike St.
Boston, MA 02141
USA
Phone
(617) 278-6616
Website
www.decimmune.com
Email Address
[email protected]
Overview
DecImmune Therapeutics is a Boston-based biotech company developing drugs for inflammation and autoimmunity.
Profile
DecImmune Therapeutics LinkedIn Company Profile
Social Media
DecImmune Therapeutics Company Twitter Account
Company News
DecImmune Therapeutics News
Facebook
DecImmune Therapeutics on Facebook
YouTube
DecImmune Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Scientific Officer
Walter Newman
  Walter Newman LinkedIn Profile  Walter Newman Twitter Account  Walter Newman News  Walter Newman on Facebook
Co-Founder
Michael Carroll
  Michael Carroll LinkedIn Profile  Michael Carroll Twitter Account  Michael Carroll News  Michael Carroll on Facebook
Co-Founder
Francis Moore
  Francis Moore LinkedIn Profile  Francis Moore Twitter Account  Francis Moore News  Francis Moore on Facebook
President
Christopher Mirabelli
  Christopher Mirabelli LinkedIn Profile  Christopher Mirabelli Twitter Account  Christopher Mirabelli News  Christopher Mirabelli on Facebook

 

 

Browse more venture capital transactions:

Prev: 1/17/2013: LoopIt venture capital transaction
Next: 1/17/2013: Celtra venture capital transaction

 

Share this article

 

About Database of VC Transactions

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.